Profusa, Inc. Common Stock (NASDAQ: PFSA) Stock Competitors & Peer Comparison

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, PFSA's ROE is +1.48%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, PFSA is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check BSX-PA's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, ABT has a market cap of 174.9B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while ABT trades at $101.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas ABT's P/E ratio is 19.40. In terms of profitability, PFSA's ROE is +1.48%, compared to ABT's ROE of +0.11%. Regarding short-term risk, PFSA is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check ABT's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, MDT has a market cap of 113.3B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while MDT trades at $88.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas MDT's P/E ratio is 16.00. In terms of profitability, PFSA's ROE is +1.48%, compared to MDT's ROE of +0.11%. Regarding short-term risk, PFSA is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check MDT's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, SYK has a market cap of 103.5B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while SYK trades at $269.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas SYK's P/E ratio is 20.16. In terms of profitability, PFSA's ROE is +1.48%, compared to SYK's ROE of +0.16%. Regarding short-term risk, PFSA is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check SYK's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, BSX has a market cap of 66.4B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while BSX trades at $44.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas BSX's P/E ratio is 14.42. In terms of profitability, PFSA's ROE is +1.48%, compared to BSX's ROE of +0.15%. Regarding short-term risk, PFSA is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check BSX's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, EW has a market cap of 49.4B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while EW trades at $85.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas EW's P/E ratio is 31.74. In terms of profitability, PFSA's ROE is +1.48%, compared to EW's ROE of +0.10%. Regarding short-term risk, PFSA is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check EW's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, DXCM has a market cap of 33B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while DXCM trades at $87.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas DXCM's P/E ratio is 34.30. In terms of profitability, PFSA's ROE is +1.48%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, PFSA is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check DXCM's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, GEHC has a market cap of 30B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while GEHC trades at $66.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas GEHC's P/E ratio is 14.56. In terms of profitability, PFSA's ROE is +1.48%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, PFSA is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check GEHC's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, PHG has a market cap of 24B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while PHG trades at $24.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas PHG's P/E ratio is 14.02. In terms of profitability, PFSA's ROE is +1.48%, compared to PHG's ROE of +0.10%. Regarding short-term risk, PFSA is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check PHG's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, ZBH has a market cap of 17.4B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while ZBH trades at $89.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas ZBH's P/E ratio is 10.58. In terms of profitability, PFSA's ROE is +1.48%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, PFSA is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check ZBH's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas ABMD's P/E ratio is 65.36. In terms of profitability, PFSA's ROE is +1.48%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, PFSA is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check ABMD's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while PEN trades at $319.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas PEN's P/E ratio is 83.48. In terms of profitability, PFSA's ROE is +1.48%, compared to PEN's ROE of +0.11%. Regarding short-term risk, PFSA is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check PEN's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas SWAV's P/E ratio is 78.76. In terms of profitability, PFSA's ROE is +1.48%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, PFSA is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check SWAV's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, SNN has a market cap of 11.2B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while SNN trades at $26.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas SNN's P/E ratio is 18.01. In terms of profitability, PFSA's ROE is +1.48%, compared to SNN's ROE of +0.12%. Regarding short-term risk, PFSA is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check SNN's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, ALGN has a market cap of 10.4B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while ALGN trades at $145.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas ALGN's P/E ratio is 13.27. In terms of profitability, PFSA's ROE is +1.48%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, PFSA is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check ALGN's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, BIO has a market cap of 10.4B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while BIO trades at $387.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas BIO's P/E ratio is 41.73. In terms of profitability, PFSA's ROE is +1.48%, compared to BIO's ROE of +0.03%. Regarding short-term risk, PFSA is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check BIO's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, BIO-B has a market cap of 10.3B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while BIO-B trades at $374.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas BIO-B's P/E ratio is -65.99. In terms of profitability, PFSA's ROE is +1.48%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, PFSA is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check BIO-B's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, GMED has a market cap of 10B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while GMED trades at $74.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas GMED's P/E ratio is 16.73. In terms of profitability, PFSA's ROE is +1.48%, compared to GMED's ROE of +0.12%. Regarding short-term risk, PFSA is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check GMED's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, BRKR has a market cap of 9.7B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while BRKR trades at $64.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas BRKR's P/E ratio is 32.17. In terms of profitability, PFSA's ROE is +1.48%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, PFSA is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check BRKR's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas MASI's P/E ratio is 44.43. In terms of profitability, PFSA's ROE is +1.48%, compared to MASI's ROE of +0.09%. Regarding short-term risk, PFSA is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check MASI's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, PODD has a market cap of 9.4B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while PODD trades at $135.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas PODD's P/E ratio is 23.13. In terms of profitability, PFSA's ROE is +1.48%, compared to PODD's ROE of +0.27%. Regarding short-term risk, PFSA is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check PODD's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, BRKRP has a market cap of 9.4B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while BRKRP trades at $468.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas BRKRP's P/E ratio is 254.78. In terms of profitability, PFSA's ROE is +1.48%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, PFSA is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check BRKRP's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, GKOS has a market cap of 9.1B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while GKOS trades at $154.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas GKOS's P/E ratio is -180.02. In terms of profitability, PFSA's ROE is +1.48%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, PFSA is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check GKOS's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, HAE has a market cap of 4.8B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while HAE trades at $106.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas HAE's P/E ratio is 21.15. In terms of profitability, PFSA's ROE is +1.48%, compared to HAE's ROE of +0.11%. Regarding short-term risk, PFSA is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check HAE's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas NARI's P/E ratio is -59.24. In terms of profitability, PFSA's ROE is +1.48%, compared to NARI's ROE of -0.00%. Regarding short-term risk, PFSA is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check NARI's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while ITGR trades at $126.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas ITGR's P/E ratio is 19.87. In terms of profitability, PFSA's ROE is +1.48%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, PFSA is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check ITGR's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, LIVN has a market cap of 4.1B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while LIVN trades at $75.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas LIVN's P/E ratio is 17.92. In terms of profitability, PFSA's ROE is +1.48%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, PFSA is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check LIVN's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while IRTC trades at $110.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas IRTC's P/E ratio is -257.67. In terms of profitability, PFSA's ROE is +1.48%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, PFSA is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check IRTC's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas AXNX's P/E ratio is -709.80. In terms of profitability, PFSA's ROE is +1.48%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, PFSA is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check AXNX's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, NEOG has a market cap of 3B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while NEOG trades at $13.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas NEOG's P/E ratio is 48.79. In terms of profitability, PFSA's ROE is +1.48%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, PFSA is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check NEOG's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while TMDX trades at $83.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas TMDX's P/E ratio is 42.59. In terms of profitability, PFSA's ROE is +1.48%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, PFSA is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check TMDX's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, BFLY has a market cap of 2.5B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while BFLY trades at $9.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas BFLY's P/E ratio is -39.19. In terms of profitability, PFSA's ROE is +1.48%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, PFSA is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check BFLY's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while AXGN trades at $43.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas AXGN's P/E ratio is 114.00. In terms of profitability, PFSA's ROE is +1.48%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, PFSA is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check AXGN's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while UFPT trades at $298.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas UFPT's P/E ratio is 30.49. In terms of profitability, PFSA's ROE is +1.48%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, PFSA is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check UFPT's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas NUVA's P/E ratio is 75.00. In terms of profitability, PFSA's ROE is +1.48%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, PFSA is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check NUVA's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, INSP has a market cap of 2B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while INSP trades at $68.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas INSP's P/E ratio is 30.31. In terms of profitability, PFSA's ROE is +1.48%, compared to INSP's ROE of +0.18%. Regarding short-term risk, PFSA is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check INSP's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while ESTA trades at $65.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas ESTA's P/E ratio is -52.08. In terms of profitability, PFSA's ROE is +1.48%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, PFSA is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check ESTA's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while NVCR trades at $16.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas NVCR's P/E ratio is -12.46. In terms of profitability, PFSA's ROE is +1.48%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, PFSA is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check NVCR's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while ATEC trades at $9.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas ATEC's P/E ratio is -165.33. In terms of profitability, PFSA's ROE is +1.48%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, PFSA is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check ATEC's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while CNMD trades at $45.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas CNMD's P/E ratio is 9.93. In terms of profitability, PFSA's ROE is +1.48%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, PFSA is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check CNMD's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas HSKA's P/E ratio is -62.49. In terms of profitability, PFSA's ROE is +1.48%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, PFSA is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check HSKA's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while IART trades at $15.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas IART's P/E ratio is 6.73. In terms of profitability, PFSA's ROE is +1.48%, compared to IART's ROE of -0.01%. Regarding short-term risk, PFSA is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check IART's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas AVNS's P/E ratio is 27.77. In terms of profitability, PFSA's ROE is +1.48%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, PFSA is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check AVNS's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while AORT trades at $23.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas AORT's P/E ratio is 38.40. In terms of profitability, PFSA's ROE is +1.48%, compared to AORT's ROE of -0.01%. Regarding short-term risk, PFSA is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check AORT's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas SILK's P/E ratio is -18.96. In terms of profitability, PFSA's ROE is +1.48%, compared to SILK's ROE of -0.35%. Regarding short-term risk, PFSA is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check SILK's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas FNA's P/E ratio is -19.83. In terms of profitability, PFSA's ROE is +1.48%, compared to FNA's ROE of -0.35%. Regarding short-term risk, PFSA is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check FNA's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while IRMD trades at $85.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas IRMD's P/E ratio is 42.81. In terms of profitability, PFSA's ROE is +1.48%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, PFSA is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check IRMD's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while ENOV trades at $18.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas ENOV's P/E ratio is 5.24. In terms of profitability, PFSA's ROE is +1.48%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, PFSA is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check ENOV's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, TNDM has a market cap of 1B. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while TNDM trades at $15.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas TNDM's P/E ratio is -16.37. In terms of profitability, PFSA's ROE is +1.48%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, PFSA is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check TNDM's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, PRCT has a market cap of 996.1M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while PRCT trades at $17.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas PRCT's P/E ratio is -9.02. In terms of profitability, PFSA's ROE is +1.48%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, PFSA is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check PRCT's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, BBNX has a market cap of 979M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while BBNX trades at $21.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas BBNX's P/E ratio is -13.19. In terms of profitability, PFSA's ROE is +1.48%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, PFSA is more volatile compared to BBNX. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check BBNX's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, LMRI has a market cap of 949.3M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while LMRI trades at $9.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas LMRI's P/E ratio is -19.22. In terms of profitability, PFSA's ROE is +1.48%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, PFSA is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check LMRI's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, BVS has a market cap of 916M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while BVS trades at $13.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas BVS's P/E ratio is 17.79. In terms of profitability, PFSA's ROE is +1.48%, compared to BVS's ROE of +0.28%. Regarding short-term risk, PFSA is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check BVS's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, CBLL has a market cap of 903.8M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while CBLL trades at $23.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas CBLL's P/E ratio is -13.53. In terms of profitability, PFSA's ROE is +1.48%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, PFSA is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check CBLL's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas CSII's P/E ratio is -20.83. In terms of profitability, PFSA's ROE is +1.48%, compared to CSII's ROE of -0.14%. Regarding short-term risk, PFSA is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check CSII's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, SIBN has a market cap of 821.3M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while SIBN trades at $18.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas SIBN's P/E ratio is -54.47. In terms of profitability, PFSA's ROE is +1.48%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, PFSA is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check SIBN's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, INMD has a market cap of 815.7M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while INMD trades at $14.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas INMD's P/E ratio is 9.85. In terms of profitability, PFSA's ROE is +1.48%, compared to INMD's ROE of +0.12%. Regarding short-term risk, PFSA is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check INMD's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, VREX has a market cap of 777.6M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while VREX trades at $18.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas VREX's P/E ratio is 19.44. In terms of profitability, PFSA's ROE is +1.48%, compared to VREX's ROE of +0.05%. Regarding short-term risk, PFSA is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check VREX's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, AHCO has a market cap of 757.8M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while AHCO trades at $5.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas AHCO's P/E ratio is 11.37. In terms of profitability, PFSA's ROE is +1.48%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, PFSA is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check AHCO's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, AVR has a market cap of 743.8M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while AVR trades at $7.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas AVR's P/E ratio is -3.94. In terms of profitability, PFSA's ROE is +1.48%, compared to AVR's ROE of -0.78%. Regarding short-term risk, PFSA is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check AVR's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, CTKB has a market cap of 740M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while CTKB trades at $5.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas CTKB's P/E ratio is -30.36. In terms of profitability, PFSA's ROE is +1.48%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, PFSA is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check CTKB's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas SRDX's P/E ratio is -34.66. In terms of profitability, PFSA's ROE is +1.48%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, PFSA is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check SRDX's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, SSII has a market cap of 590.4M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while SSII trades at $2.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas SSII's P/E ratio is -49.17. In terms of profitability, PFSA's ROE is +1.48%, compared to SSII's ROE of -0.27%. Regarding short-term risk, PFSA is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check SSII's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, KIDS has a market cap of 581.5M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while KIDS trades at $22.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas KIDS's P/E ratio is -19.19. In terms of profitability, PFSA's ROE is +1.48%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, PFSA is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check KIDS's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas APEN's P/E ratio is -9.43. In terms of profitability, PFSA's ROE is +1.48%, compared to APEN's ROE of -0.85%. Regarding short-term risk, PFSA is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check APEN's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, DCTH has a market cap of 555.1M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while DCTH trades at $16.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas DCTH's P/E ratio is 1608.00. In terms of profitability, PFSA's ROE is +1.48%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, PFSA is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check DCTH's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, PFSA's ROE is +1.48%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, PFSA is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check ZIMV's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, CERS has a market cap of 525M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while CERS trades at $2.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas CERS's P/E ratio is -86.54. In terms of profitability, PFSA's ROE is +1.48%, compared to CERS's ROE of -0.10%. Regarding short-term risk, PFSA is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check CERS's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, TCMD has a market cap of 516.3M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while TCMD trades at $22.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas TCMD's P/E ratio is 21.19. In terms of profitability, PFSA's ROE is +1.48%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, PFSA is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check TCMD's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, PACB has a market cap of 490.8M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while PACB trades at $1.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas PACB's P/E ratio is -3.85. In terms of profitability, PFSA's ROE is +1.48%, compared to PACB's ROE of -49.62%. Regarding short-term risk, PFSA is more volatile compared to PACB. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check PACB's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, NPCE has a market cap of 476.3M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while NPCE trades at $13.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas NPCE's P/E ratio is -24.51. In terms of profitability, PFSA's ROE is +1.48%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, PFSA is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check NPCE's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, SGHT has a market cap of 472.3M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while SGHT trades at $8.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas SGHT's P/E ratio is -15.50. In terms of profitability, PFSA's ROE is +1.48%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, PFSA is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check SGHT's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, CLPT has a market cap of 437.8M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while CLPT trades at $14.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas CLPT's P/E ratio is -12.37. In terms of profitability, PFSA's ROE is +1.48%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, PFSA is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check CLPT's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, SENS has a market cap of 432.2M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while SENS trades at $10.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas SENS's P/E ratio is -4.64. In terms of profitability, PFSA's ROE is +1.48%, compared to SENS's ROE of -1.66%. Regarding short-term risk, PFSA is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check SENS's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, OFIX has a market cap of 370.3M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while OFIX trades at $9.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas OFIX's P/E ratio is -5.97. In terms of profitability, PFSA's ROE is +1.48%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, PFSA is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check OFIX's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas SMLR's P/E ratio is 3.92. In terms of profitability, PFSA's ROE is +1.48%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, PFSA is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check SMLR's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, CV has a market cap of 308.3M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while CV trades at $6.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas CV's P/E ratio is -9.79. In terms of profitability, PFSA's ROE is +1.48%, compared to CV's ROE of -1.78%. Regarding short-term risk, PFSA is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check CV's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, TMCI has a market cap of 294.5M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while TMCI trades at $4.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas TMCI's P/E ratio is -4.83. In terms of profitability, PFSA's ROE is +1.48%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, PFSA is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check TMCI's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, RCEL has a market cap of 287.7M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while RCEL trades at $11.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas RCEL's P/E ratio is -8.04. In terms of profitability, PFSA's ROE is +1.48%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, PFSA is more volatile compared to RCEL. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check RCEL's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, CATX has a market cap of 284.5M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while CATX trades at $2.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas CATX's P/E ratio is -1.88. In terms of profitability, PFSA's ROE is +1.48%, compared to CATX's ROE of -0.42%. Regarding short-term risk, PFSA is more volatile compared to CATX. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check CATX's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, TLSI has a market cap of 283.9M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while TLSI trades at $4.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas TLSI's P/E ratio is -2.74. In terms of profitability, PFSA's ROE is +1.48%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, PFSA is more volatile compared to TLSI. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check TLSI's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, INFU has a market cap of 256.2M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while INFU trades at $12.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas INFU's P/E ratio is 30.96. In terms of profitability, PFSA's ROE is +1.48%, compared to INFU's ROE of +0.15%. Regarding short-term risk, PFSA is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check INFU's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas MGRM's P/E ratio is -12.00. In terms of profitability, PFSA's ROE is +1.48%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, PFSA is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check MGRM's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, ELMD has a market cap of 230.5M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while ELMD trades at $27.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas ELMD's P/E ratio is 21.25. In terms of profitability, PFSA's ROE is +1.48%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, PFSA is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check ELMD's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas NVRO's P/E ratio is -1.91. In terms of profitability, PFSA's ROE is +1.48%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, PFSA is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check NVRO's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, PROF has a market cap of 203.5M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while PROF trades at $5.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas PROF's P/E ratio is -5.71. In terms of profitability, PFSA's ROE is +1.48%, compared to PROF's ROE of -0.56%. Regarding short-term risk, PFSA is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check PROF's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, STIM has a market cap of 196.2M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while STIM trades at $2.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas STIM's P/E ratio is -6.41. In terms of profitability, PFSA's ROE is +1.48%, compared to STIM's ROE of -1.51%. Regarding short-term risk, PFSA is more volatile compared to STIM. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check STIM's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, RXST has a market cap of 195.8M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while RXST trades at $4.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas RXST's P/E ratio is -4.19. In terms of profitability, PFSA's ROE is +1.48%, compared to RXST's ROE of -0.17%. Regarding short-term risk, PFSA is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check RXST's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas BSGM's P/E ratio is -5.81. In terms of profitability, PFSA's ROE is +1.48%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, PFSA is more volatile compared to BSGM. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check BSGM's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas MDGS's P/E ratio is -0.27. In terms of profitability, PFSA's ROE is +1.48%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, PFSA is more volatile compared to MDGS. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check MDGS's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, FOCL has a market cap of 172M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while FOCL trades at $4.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas FOCL's P/E ratio is -4.44. In terms of profitability, PFSA's ROE is +1.48%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, PFSA is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check FOCL's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas QIPT's P/E ratio is -15.87. In terms of profitability, PFSA's ROE is +1.48%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, PFSA is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check QIPT's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, LUCD has a market cap of 159.9M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while LUCD trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas LUCD's P/E ratio is -2.26. In terms of profitability, PFSA's ROE is +1.48%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, PFSA is more volatile compared to LUCD. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check LUCD's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, QSI has a market cap of 157.7M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while QSI trades at $0.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas QSI's P/E ratio is -1.73. In terms of profitability, PFSA's ROE is +1.48%, compared to QSI's ROE of -0.47%. Regarding short-term risk, PFSA is more volatile compared to QSI. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check QSI's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, QTRX has a market cap of 149.8M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while QTRX trades at $3.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas QTRX's P/E ratio is -1.25. In terms of profitability, PFSA's ROE is +1.48%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, PFSA is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check QTRX's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, INGN has a market cap of 141.6M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while INGN trades at $5.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas INGN's P/E ratio is -5.75. In terms of profitability, PFSA's ROE is +1.48%, compared to INGN's ROE of -0.13%. Regarding short-term risk, PFSA is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check INGN's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas ICAD's P/E ratio is -20.37. In terms of profitability, PFSA's ROE is +1.48%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, PFSA is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check ICAD's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, ECOR has a market cap of 102.3M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while ECOR trades at $11.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas ECOR's P/E ratio is -6.76. In terms of profitability, PFSA's ROE is +1.48%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, PFSA is more volatile compared to ECOR. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check ECOR's competition here

Profusa, Inc. Common Stock (NASDAQ: PFSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFSA stands at 3.3M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, PFSA is priced at $3.03 on the NASDAQ, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFSA currently has a P/E ratio of -0.03, whereas HJLI's P/E ratio is N/A. In terms of profitability, PFSA's ROE is +1.48%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, PFSA is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for PFSA.Check HJLI's competition here